TH9507 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Metformin - widely used in treatment of diabetes mellitus type 2 Phenformin - withdrawn from the market in most countries due to toxic effects Buformin - withdrawn from the market due to toxic effects
A variety of biological activities have been discovered from isolated sv-LAAOs including cytotoxic, antibacterial, antiviral, and antiparasitic activities as well as platelet aggregation effects. These activities can be defined by the enzyme's ability to provoke oxidative stress by forming oxygen radicals and hydrogen peroxide. The particular mechanism of action of sv-LAAOs in terms of platelet aggregation has been determined less clear, because some sv-LAAOs are known to create aggregates and some are known to be anti-aggregating factors. Recent work has shown that LAAO binds directly to the surface of bacterial and mammalian cancer cells, concentrating hydrogen peroxide production at the cell membrane interface. This localized accumulation leads to enhanced oxidative damage, supporting a dual mechanism involving both catalytic activity and membrane interaction. In recent studies, it has been shown that LAAOs have been isolated from the skin and/or gill mucous secretions of rockfish, great sculpin, and flounder. The presence of these enzymes were identified to be a unique type of antibacterial protein in the external defense employed by certain fish species.
"A Fighter From the Ground Up." Popular Science, July 1943, one of earliest detailed articles on P-51A Archived 23 October 2013 at the Wayback Machine "Wild Horses of the Sky," Popular Mechanics, November 1943 Joe Baugher, North American P-51 Mustang Archived 23 July 2011 at the Wayback Machine Camouflage and Markings of P-51 Mustang Parts 1–4 USAAF plus Allison engine versions RAF and Commonwealth Archived 1 March 2012 at the Wayback Machine Allison-powered Mustang performance test reports; 1940, 1942, 1943, 1944 Archived 22 December 2008 at the Wayback Machine P-51B Mustang performance test report, May 1943 Archived 9 January 2008 at the Wayback Machine P-51 combat reports Archived 23 December 2007 at the Wayback Machine NACA-WR-L-566 "Flying qualities and stalling characteristics of North American XP-51 airplane", April 1943. (PDF) North American P-51 profile, photos and technical details for each mk "Flight Characteristics of the North American P-51 Mustang: How to Fly the P-51 Mustang" on YouTube "Mustang Squadron" a 1942 Flight article "Army Co-Op Mustang" a 1942 Flight article "Unobtrusive Cleverness" a 1942 Flight article "Long Range Mustang" a 1944 Flight article P-51 in Flight Over California (1942) Flight manual Mustang P-51A Archived 15 May 2024 at the Wayback Machine – The Museum of Flight Digital Collections Pilot training manual for the Mustang P-51 Archived 8 October 2024 at the Wayback Machine – The Museum of Flight Digital Collections
=== Small molecules from the human microbiota === In 2014, Fischbach and his laboratory published a survey of biosynthetic genes in the human microbiome, describing the ability of human-associated microbes to produce thiopeptide antibiotics. The Fischbach lab discovered that the gut commensal Bacteroides fragilis produces the immune modulatory sphingolipid alpha-galactosylceramide, showed that the production of neurotransmitters is common among commensal gut bacteria, and discovered the biosynthetic pathway for a common class of bile acids produced by gut bacteria.
Sources: en.wikipedia.org
The technique of knocking down genes using RNAi therapeutics has demonstrated success in randomized controlled clinical studies. These medications are a growing class of siRNA-based drugs that decrease the expression of proteins encoded by certain genes. To date, five RNAi medications have been approved by regulatory authorities in the US and Europe: patisiran (2018), givosiran (2019), lumasiran (2020), inclisiran (2020 in Europe with anticipated US approval in 2021), and vutrisiran (2022). While all of the current regulatory body approved RNAi therapeutics focus on diseases that originate in the liver, additional medications under investigation target a host of disease areas including cardiovascular diseases, bleeding disorders, alcohol use disorders, cystic fibrosis, gout, carcinoma, and eye disorders. Patisiran is the first double stranded siRNA-based medication approved in 2018 and developed by Alnylam Pharmaceuticals. Patisiran uses the RNAi cascade to suppress the gene that codes for TTR (transthryetin). Mutations in this gene may cause the misfolding of a protein responsible for hereditary ATTR amyloidosis. To achieve therapeutic response, patisiran is encased by a lipid nanoparticle membrane that facilitates crossover into the cytoplasm. Once inside the cell, the siRNA begins processing by the enzyme Dicer. Patisiran is administered by a healthcare professional through an intravenous infusion with dosing based on body weight. Warnings and precautions include risk of infusion-related reactions and reduced vitamin A levels (serum).
==== Bones ==== In mice, irisin released from skeletal muscle during exercise acts directly on bone by increasing cortical bone mineral density, bone perimeter and polar moment of inertia. Irisin regulates bone remodeling and bone metabolism in animal models and humans.
== External links == Official website Example SWAPO Party Youth League web page. "Latest from the SPYL Frontlines". spyl.swapo.party. SWAPO Party Youth League. 28 August 2012. Archived from the original on 28 August 2012. Retrieved 7 November 2024.
The Gunditjmara, a local Aboriginal Australian people in south-western Victoria, Australia, may have raised short-finned eels as early as about 4,580 BCE. Evidence indicates they developed about 100 km2 (39 sq mi) of volcanic floodplains in the vicinity of Lake Condah into a complex of channels and dams, and used woven traps to capture eels, and to preserve them to eat all year round. The local Budj Bim Cultural Landscape, a World Heritage Site, is one of the oldest known aquaculture sites in the world. Anthropologist Peter Sutton has disputed that these eel trapping systems qualify as aquaculture as there is no evidence they involved the breeding, feeding, protecting, or rearing of eels. Oral tradition in China tells of the culture of the common carp, Cyprinus carpio, as long ago as 2000–2100 BCE (around 4,000 years BP), but the earliest significant evidence lies in the literature, in the earliest monograph on fish culture called The Classic of Fish Culture, by Fan Li, written around 475 BCE (c. 2475 BP). Another ancient Chinese guide to aquaculture, wriiten by Yang Yu Jing around 460 BCE, shows that carp farming was becoming more sophisticated. The Jiahu site in China has circumstantial archeological evidence as possibly the oldest aquaculture locations, dating from 6200BCE (about 8,200 years BP), but this is speculative. When the waters subsided after river floods, some fish, mainly carp, were trapped in lakes. Early aquaculturists fed their brood using nymphs and silkworm faeces, and ate them.
Leo Tolstoy's epic novel War and Peace recounts Napoleon's wars between 1805 and 1812 (especially the disastrous 1812 invasion of Russia and subsequent retreat) from a Russian perspective. Stendhal's novel The Charterhouse of Parma opens with a ground-level recounting of the Battle of Waterloo and the subsequent chaotic retreat of French forces. Les Misérables by Victor Hugo takes place against the backdrop of the Napoleonic Wars and subsequent decades, and in its unabridged form contains an epic telling of the Battle of Waterloo. Adieu is a novella by Honoré de Balzac in which can be found a short description of the French retreat from Russia, particularly the battle of Berezina, where the fictional couple of the story are tragically separated. Years later after imprisonment, the husband returns to find his wife still in a state of utter shock and amnesia. He has the battle and their separation reenacted, hoping the memory will heal her state. William Makepeace Thackeray's novel Vanity Fair takes place during the 1815 Napoleonic War – one of its protagonists dies at the Battle of Waterloo. Thackeray states in Chapter XXX "We do not claim to rank among the military novelists. Our place is with the non-combatants. When the decks are cleared for action we go below and wait meekly." And indeed he presents no descriptions of military leaders, strategy, or combat; he describes anxious non-combatants waiting in Brussels for news.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.